Annual CFF
$4.65 M
-$6.03 M-56.42%
30 June 2024
Summary:
InMed Pharmaceuticals annual cash flow from financing activities is currently $4.65 million, with the most recent change of -$6.03 million (-56.42%) on 30 June 2024. During the last 3 years, it has fallen by -$6.20 million (-57.12%). INM annual CFF is now -75.00% below its all-time high of $18.62 million, reached on 30 June 2018.INM Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
$838.20 K
+$838.00 K+419000.00%
30 September 2024
Summary:
InMed Pharmaceuticals quarterly cash flow from financing activities is currently $838.20 thousand, with the most recent change of +$838.00 thousand (+419000.00%) on 30 September 2024. Over the past year, it has increased by +$838.20 thousand (+100.00%). INM quarterly CFF is now -92.30% below its all-time high of $10.88 million, reached on 30 September 2021.INM Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$5.49 M
+$838.20 K+18.01%
30 September 2024
Summary:
InMed Pharmaceuticals TTM cash flow from financing activities is currently $5.49 million, with the most recent change of +$838.20 thousand (+18.01%) on 30 September 2024. Over the past year, it has increased by +$240.90 thousand (+4.59%). INM TTM CFF is now -74.81% below its all-time high of $21.80 million, reached on 30 September 2021.INM TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
INM Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -56.4% | +100.0% | +4.6% |
| 3 y3 years | -57.1% | -92.3% | -74.8% |
| 5 y5 years | +2141.9% | +100.0% | +2661.4% |
INM Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -69.1% | at low | -92.3% | +200.3% | -74.8% | +19.6% |
| 5 y | 5 years | -69.1% | >+9999.0% | -92.3% | +200.3% | -74.8% | +5845.2% |
| alltime | all time | -75.0% | +3389.2% | -92.3% | +158.0% | -74.8% | +825.5% |
InMed Pharmaceuticals Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $838.20 K(>+9900.0%) | $5.49 M(+18.0%) |
| June 2024 | $4.65 M(-56.4%) | $200.00(>+9900.0%) | $4.65 M(+0.0%) |
| Mar 2024 | - | $0.00(-100.0%) | $4.65 M(+1.4%) |
| Dec 2023 | - | $4.65 M(>+9900.0%) | $4.59 M(-12.6%) |
| Sept 2023 | - | $0.00(0.0%) | $5.25 M(-50.8%) |
| June 2023 | $10.68 M(-29.1%) | $0.00(-100.0%) | $10.68 M(-32.1%) |
| Mar 2023 | - | -$63.70 K(-101.2%) | $15.73 M(-0.2%) |
| Dec 2022 | - | $5.32 M(-2.1%) | $15.77 M(+64.0%) |
| Sept 2022 | - | $5.43 M(+7.5%) | $9.62 M(-36.2%) |
| June 2022 | $15.07 M(+38.8%) | $5.05 M(<-9900.0%) | $15.07 M(+51.7%) |
| Mar 2022 | - | -$29.30 K(-96.5%) | $9.94 M(-29.1%) |
| Dec 2021 | - | -$836.10 K(-107.7%) | $14.01 M(-35.7%) |
| Sept 2021 | - | $10.88 M(<-9900.0%) | $21.80 M(+100.9%) |
| June 2021 | $10.85 M(<-9900.0%) | -$83.20 K(-102.1%) | $10.85 M(-0.5%) |
| Mar 2021 | - | $4.04 M(-41.9%) | $10.91 M(+58.9%) |
| Dec 2020 | - | $6.96 M(<-9900.0%) | $6.86 M(-7277.9%) |
| Sept 2020 | - | -$64.60 K(+108.4%) | -$95.60 K(+208.4%) |
| June 2020 | -$31.00 K(-114.9%) | -$31.00 K(<-9900.0%) | -$31.00 K(-115.6%) |
| Dec 2019 | - | $0.00(0.0%) | $199.30 K(+0.2%) |
| Sept 2019 | - | $0.00(-100.0%) | $198.90 K(-4.2%) |
| June 2019 | $207.60 K(-98.9%) | $54.00 K(-62.8%) | $207.60 K(-98.0%) |
| Mar 2019 | - | $145.30 K(<-9900.0%) | $10.61 M(-9.5%) |
| Dec 2018 | - | -$400.00(-104.6%) | $11.73 M(-35.1%) |
| Sept 2018 | - | $8700.00(-99.9%) | $18.08 M(-2.9%) |
| June 2018 | $18.62 M(+148.2%) | $10.46 M(+728.8%) | $18.62 M(+53.9%) |
| Mar 2018 | - | $1.26 M(-80.1%) | $12.09 M(-7.7%) |
| Dec 2017 | - | $6.35 M(+1059.4%) | $13.10 M(+68.0%) |
| Sept 2017 | - | $547.30 K(-86.1%) | $7.80 M(+3.9%) |
| June 2017 | $7.50 M(+2399.5%) | $3.94 M(+73.6%) | $7.50 M(+104.8%) |
| Mar 2017 | - | $2.27 M(+118.3%) | $3.66 M(+152.9%) |
| Dec 2016 | - | $1.04 M(+313.8%) | $1.45 M(+166.7%) |
| Sept 2016 | - | $251.30 K(+146.1%) | $543.20 K(+80.9%) |
| June 2016 | $300.10 K(-82.8%) | $102.10 K(+85.0%) | $300.20 K(-71.5%) |
| Mar 2016 | - | $55.20 K(-59.0%) | $1.05 M(-36.9%) |
| Dec 2015 | - | $134.60 K(+1521.7%) | $1.67 M(+1.3%) |
| Sept 2015 | - | $8300.00(-99.0%) | $1.64 M(-5.5%) |
| June 2015 | $1.74 M(+169.2%) | $853.40 K(+27.4%) | $1.74 M(+13.5%) |
| Mar 2015 | - | $669.80 K(+491.2%) | $1.53 M(+77.6%) |
| Dec 2014 | - | $113.30 K(+9.0%) | $863.60 K(+15.1%) |
| Sept 2014 | - | $103.90 K(-83.9%) | $750.30 K(+16.1%) |
| June 2014 | $646.40 K | $646.40 K(>+9900.0%) | $646.40 K(>+9900.0%) |
| Mar 2014 | - | $0.00(0.0%) | $0.00(0.0%) |
| Dec 2013 | - | $0.00(0.0%) | $0.00(0.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2013 | - | $0.00(0.0%) | $0.00(-100.0%) |
| June 2013 | $0.00(-100.0%) | - | - |
| Sept 2011 | - | $0.00(-100.0%) | $788.70 K(-0.5%) |
| June 2011 | $792.60 K(+305.6%) | $6200.00(-99.2%) | $792.60 K(-5.2%) |
| Mar 2011 | - | $772.10 K(+7324.0%) | $836.30 K(+634.9%) |
| Dec 2010 | - | $10.40 K(+166.7%) | $113.80 K(-21.2%) |
| Sept 2010 | - | $3900.00(-92.2%) | $144.50 K(-26.0%) |
| June 2010 | $195.40 K(-238.1%) | $49.90 K(+0.6%) | $195.40 K(-468.0%) |
| Mar 2010 | - | $49.60 K(+20.7%) | -$53.10 K(-33.8%) |
| Dec 2009 | - | $41.10 K(-25.0%) | -$80.20 K(-44.0%) |
| Sept 2009 | - | $54.80 K(-127.6%) | -$143.10 K(+1.2%) |
| June 2009 | -$141.50 K(-122.6%) | -$198.60 K(-982.7%) | -$141.40 K(-712.1%) |
| Mar 2009 | - | $22.50 K(-203.2%) | $23.10 K(-104.0%) |
| Dec 2008 | - | -$21.80 K(-138.6%) | -$580.00 K(-244.8%) |
| Sept 2008 | - | $56.50 K(-265.7%) | $400.50 K(-36.0%) |
| June 2008 | $626.20 K(-57.8%) | -$34.10 K(-94.1%) | $626.20 K(-44.4%) |
| Mar 2008 | - | -$580.60 K(-160.6%) | $1.13 M(-48.1%) |
| Dec 2007 | - | $958.70 K(+239.7%) | $2.17 M(+68.8%) |
| Sept 2007 | - | $282.20 K(-39.5%) | $1.29 M(-13.3%) |
| June 2007 | $1.48 M(+128.9%) | $466.70 K(+0.3%) | $1.48 M(+59.8%) |
| Mar 2007 | - | $465.10 K(+537.1%) | $928.40 K(+41.0%) |
| Dec 2006 | - | $73.00 K(-84.8%) | $658.60 K(-21.7%) |
| Sept 2006 | - | $479.10 K(-639.5%) | $841.60 K(+29.8%) |
| June 2006 | $648.20 K(-37.5%) | -$88.80 K(-145.5%) | $648.20 K(-191.5%) |
| Mar 2006 | - | $195.30 K(-23.7%) | -$708.80 K(-6.4%) |
| Dec 2005 | - | $256.00 K(-10.4%) | -$757.10 K(-166.5%) |
| Sept 2005 | - | $285.70 K(-119.8%) | $1.14 M(+9.8%) |
| June 2005 | $1.04 M(+142.0%) | -$1.45 M(-1083.5%) | $1.04 M(-64.8%) |
| Mar 2005 | - | $147.00 K(-93.2%) | $2.95 M(-3.5%) |
| Dec 2004 | - | $2.15 M(+1066.6%) | $3.05 M(+345.9%) |
| Sept 2004 | - | $184.40 K(-60.2%) | $684.80 K(+59.9%) |
| July 2004 | $428.40 K(-25.2%) | $463.20 K(+81.9%) | $428.40 K(-20.4%) |
| Apr 2004 | - | $254.70 K(-217.1%) | $538.20 K(+89.8%) |
| Jan 2004 | - | -$217.50 K(+202.1%) | $283.50 K(-43.4%) |
| Oct 2003 | - | -$72.00 K(-112.6%) | $501.00 K(-12.6%) |
| July 2003 | $573.00 K(>+9900.0%) | $573.00 K(>+9900.0%) | $573.00 K(>+9900.0%) |
| Apr 2003 | - | $0.00(0.0%) | $0.00(0.0%) |
| Jan 2003 | - | $0.00(0.0%) | $0.00(0.0%) |
| Oct 2002 | - | $0.00(0.0%) | $0.00(0.0%) |
| July 2002 | $0.00(-100.0%) | $0.00(0.0%) | $0.00(0.0%) |
| Apr 2002 | - | $0.00(0.0%) | $0.00(0.0%) |
| Jan 2002 | - | $0.00(0.0%) | $0.00(0.0%) |
| Oct 2001 | - | $0.00 | $0.00 |
| July 2001 | $2.21 M | - | - |
FAQ
- What is InMed Pharmaceuticals annual cash flow from financing activities?
- What is the all time high annual CFF for InMed Pharmaceuticals?
- What is InMed Pharmaceuticals annual CFF year-on-year change?
- What is InMed Pharmaceuticals quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for InMed Pharmaceuticals?
- What is InMed Pharmaceuticals quarterly CFF year-on-year change?
- What is InMed Pharmaceuticals TTM cash flow from financing activities?
- What is the all time high TTM CFF for InMed Pharmaceuticals?
- What is InMed Pharmaceuticals TTM CFF year-on-year change?
What is InMed Pharmaceuticals annual cash flow from financing activities?
The current annual CFF of INM is $4.65 M
What is the all time high annual CFF for InMed Pharmaceuticals?
InMed Pharmaceuticals all-time high annual cash flow from financing activities is $18.62 M
What is InMed Pharmaceuticals annual CFF year-on-year change?
Over the past year, INM annual cash flow from financing activities has changed by -$6.03 M (-56.42%)
What is InMed Pharmaceuticals quarterly cash flow from financing activities?
The current quarterly CFF of INM is $838.20 K
What is the all time high quarterly CFF for InMed Pharmaceuticals?
InMed Pharmaceuticals all-time high quarterly cash flow from financing activities is $10.88 M
What is InMed Pharmaceuticals quarterly CFF year-on-year change?
Over the past year, INM quarterly cash flow from financing activities has changed by +$838.20 K (+100.00%)
What is InMed Pharmaceuticals TTM cash flow from financing activities?
The current TTM CFF of INM is $5.49 M
What is the all time high TTM CFF for InMed Pharmaceuticals?
InMed Pharmaceuticals all-time high TTM cash flow from financing activities is $21.80 M
What is InMed Pharmaceuticals TTM CFF year-on-year change?
Over the past year, INM TTM cash flow from financing activities has changed by +$240.90 K (+4.59%)